Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Dillon

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
Bioorganic & Medicinal Chemistry Letters|January 5, 2010
Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonistChristine E Brotherton-Pleiss, Michael P Dillon, Anthony P D W Ford, et al.
British Journal of Pharmacology|July 2, 2010
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonistJoel R Gever, Rothschild Soto, Robert A Henningsen, et al.
Biochemistry|December 22, 2004
Harmane and harmalan are bioactive components of classical clonidine-displacing substanceChristine A Parker, Neil J Anderson, Emma S J Robinson, et al.
ACS Medicinal Chemistry Letters|August 22, 2018
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug ConjugatesAlexei S Karpov, Tinya Abrams, Suzanna Clark, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR InhibitorsPaul A Barsanti, Yue Pan, Yipin Lu, et al.
Journal of Medicinal Chemistry|December 20, 2016
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) MethyltransferaseAndreas Lingel, Martin Sendzik, Ying Huang, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|January 17, 2017
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer EfficacyYing Huang, Jeff Zhang, Zhengtian Yu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload OptimizationAlexei S Karpov, Cristina M Nieto-Oberhuber, Tinya Abrams, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
Bioorganic & Medicinal Chemistry Letters|January 5, 2010
Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonistChristine E Brotherton-Pleiss, Michael P Dillon, Anthony P D W Ford, et al.
British Journal of Pharmacology|July 2, 2010
AF-353, a novel, potent and orally bioavailable P2X3/P2X2/3 receptor antagonistJoel R Gever, Rothschild Soto, Robert A Henningsen, et al.
Biochemistry|December 22, 2004
Harmane and harmalan are bioactive components of classical clonidine-displacing substanceChristine A Parker, Neil J Anderson, Emma S J Robinson, et al.
ACS Medicinal Chemistry Letters|August 22, 2018
Nicotinamide Phosphoribosyltransferase Inhibitor as a Novel Payload for Antibody-Drug ConjugatesAlexei S Karpov, Tinya Abrams, Suzanna Clark, et al.
ACS Medicinal Chemistry Letters|January 16, 2015
Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR InhibitorsPaul A Barsanti, Yue Pan, Yipin Lu, et al.
Journal of Medicinal Chemistry|December 20, 2016
Structure-Guided Design of EED Binders Allosterically Inhibiting the Epigenetic Polycomb Repressive Complex 2 (PRC2) MethyltransferaseAndreas Lingel, Martin Sendzik, Ying Huang, et al.
Cancer Research|January 19, 2018
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAFWenlin Shao, Yuji M Mishina, Yun Feng, et al.
Journal of Medicinal Chemistry|January 17, 2017
Discovery of First-in-Class, Potent, and Orally Bioavailable Embryonic Ectoderm Development (EED) Inhibitor with Robust Anticancer EfficacyYing Huang, Jeff Zhang, Zhengtian Yu, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
ACS Medicinal Chemistry Letters|December 21, 2019
Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload OptimizationAlexei S Karpov, Cristina M Nieto-Oberhuber, Tinya Abrams, et al.
Pageof 9